Medical network - April 6, according to flush the data as of April 1, A shares A total of 114 listed pharmaceutical biotechnology company released 2016 annual report, including 84 listed companies performance year-on-year growth, accounted for about 74%. According to statistics, the 114 listed in the biological medicine enterprise, 97 listed companies cash dividends, proposed 85%. 

 

High drug sales gross profit margin has been one of the focus of capital market. Flush, according to data from 25 sales gross profit margin of listed companies by more than 70%. 

 

More than eighty percent company intends to cash dividends 

 

Data show that last year net profit growth of 31 listed companies spend one hundred million yuan. The new and into 2016 net profit attributable to shareholders of listed companies than the value increases about $800 million in 2015, for the first. 

 

Out the survey, chemical pharmaceutical field 41 issued 2016 transcripts of listed companies, including 32 listed companies performance year-on-year growth; Biological products field 16 listed company issued 2016 transcripts, 14 listed company performance for growth; 31 listed companies in Chinese medicine, 18 listed companies earnings growth; Pharmaceutical business section 12 just huatong medical performance of listed companies fell; Medical instrument plate nine listed companies YangPu medical, sanxin, and three biological performance decline; Medical services sector five listed companies, jinling pharmaceutical, medical performance decline. 

 

When regulators advocate listed companies pay dividends, medicine, biological dividends of listed companies is positive. 

 

As of April 1, the medical listed companies have 97 listed companies cash dividends proposed, including 37 cash dividends of listed companies a total of one hundred million yuan. Harbin pharmaceutical co, step length pharmaceutical cash dividend amount exceeds one billion yuan. 

 

Harbin pharmaceutical shares in 2016 annual report, according to the company profit situation and need to return for shareholders and deliberated by the board of directors of the company, the company 2016 annual profit distribution plan is: in a total of about 2.54 billion shares of base, every 10 shares distributed to all the shareholders according to the 5 yuan (including tax), cash dividend distribution of cash dividend of about 1.27 billion yuan. 

 

Step pharmaceutical 2016 annual report, passed by the board of directors of the company 2016 annual profit distribution plan is: through December 31, 2016, the company's total share capital of 681.8 million shares for the base, using undistributed profit every 10 shares allocated to all the shareholders in cash dividend of 16.14 yuan (including tax), a total of distributing cash dividend of about 1.1 billion yuan (including tax).